paclitaxel,cisplatin,gemcitabine
Not Tagged
[]
 1815 in #1l adv cholangio/gb cancer (67% ihcc, 17% ehcc, 16% gb) shows no stat significant median os diff and orr 31 vs 22% with cis/gem/abraxane vs cis/gem w/trend towards benefit in locally adv and gb subsets, several g5 aes w/triplet #gi23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope